Search results for " Adverse effects"

showing 10 items of 20 documents

Adult rat myelin enhances axonal outgrowth from neural stem cells.

2018

Axon regeneration after spinal cord injury (SCI) is attenuated by growth inhibitory molecules associated with myelin. We report that rat myelin stimulated the growth of axons emerging from rat neural progenitor cells (NPCs) transplanted into sites of SCI in adult rat recipients. When plated on a myelin substrate, neurite outgrowth from rat NPCs and from human induced pluripotent stem cell (iPSC)-derived neural stem cells (NSCs) was enhanced threefold. In vivo, rat NPCs and human iPSC-derived NSCs extended greater numbers of axons through adult central nervous system white matter than through gray matter and preferentially associated with rat host myelin. Mechanistic investigations excluded …

0301 basic medicineAgingNeuronalNudeMessengerNeurodegenerativeInbred C57BLRegenerative MedicineMedical and Health SciencesMyelinMiceNeural Stem CellsStem Cell Research - Nonembryonic - HumanCyclic AMPAxonPhosphorylationGray MatterInduced pluripotent stem cellExtracellular Signal-Regulated MAP KinasesSpinal Cord InjuryMyelin SheathInbred F344Neuronal growth regulator 1Stem Cell Research - Induced Pluripotent Stem Cell - HumanChemistryGeneral MedicineBiological SciencesWhite MatterNeural stem cellCell biologymedicine.anatomical_structureSpinal Cord5.1 PharmaceuticalsNeurologicalFemaleStem Cell Research - Nonembryonic - Non-HumanDevelopment of treatments and therapeutic interventionsPhysical Injury - Accidents and Adverse EffectsNeuriteCell Adhesion Molecules NeuronalCentral nervous systemNeuronal OutgrowthArticleWhite matter03 medical and health sciencesRats NudemedicineAnimalsHumansRNA MessengerStem Cell Research - Embryonic - HumanTraumatic Head and Spine InjuryTransplantationStem Cell Research - Induced Pluripotent Stem CellNeurosciencesStem Cell ResearchRats Inbred F344AxonsRatsMice Inbred C57BL030104 developmental biologynervous systemChondroitin Sulfate ProteoglycansRNACell Adhesion Molecules
researchProduct

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the Europe…

2020

Background Irreversible sensorineural hearing loss is a common side effect of platinum treatment with the potential to significantly impair the neurocognitive, social and educational development of childhood cancer survivors. Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in the FDA drug label and a pharmacogenetic guideline. The aim of this cross-sectional cohort study was to confirm the genetic associations in a large pan-European population and to evaluate the diagnostic accuracy of the genetic…

0301 basic medicineOncologyMaleCancer ResearchCandidate genePharmacogenomic VariantsCancer survivorsCHILDRENAnti-neoplastic drugsVARIANTSOCT2Carboplatin0302 clinical medicineHearingRisk FactorsNeoplasmsTPMTHearing / drug effectsProspective StudiesAge of OnsetChild610 Medicine & healthPREDICTORSmedia_commonHearing Loss Sensorineural / physiopathologyeducation.field_of_studyddc:618Thiopurine methyltransferasebiologycarboplatin [Cisplatin]Neoplasms / drug therapyOrganic Cation Transporter 2EuropeOncologyCisplatin: carboplatinCisplatin / adverse effects030220 oncology & carcinogenesisChild PreschoolOrganic Cation Transporter 2 / geneticsFemaleSENSITIVITYChildhood cancer360 Social problems & social servicesCohort studyDrug-induced ototoxicitymedicine.medical_specialtyINDUCED HEARING-LOSSAdolescentMulticenter cohort studyHearing Loss SensorineuralPopulationAdverse drug reactionAntineoplastic AgentsPolymorphism Single NucleotideRisk AssessmentHearing Loss Sensorineural / chemically inducedCarboplatin / adverse effects03 medical and health sciencesACYP2OtotoxicitySDG 3 - Good Health and Well-beingInternal medicinemedicineGenetic predispositionmedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseCISPLATIN-INDUCED OTOTOXICITYEuropean unioneducationGenetic Association StudiesGenetic associationRetrospective Studiesbusiness.industryAntineoplastic Agents / adverse effectsInfant NewbornInfantOdds ratioGuidelinemedicine.diseaseOtotoxicityCOMTPharmacogenomic Testing030104 developmental biologyCross-Sectional StudiesPharmacogeneticsbiology.proteinGenetic markersHearing Loss Sensorineural / geneticsCisplatinbusinessPharmacogenetics
researchProduct

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…

2013

PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …

Cancer ResearchTime FactorsLymphomamedicine.medical_treatmentGonadotropin-Releasing Hormone -- agonistsPrimary Ovarian InsufficiencyTriptorelin Pamoate -- therapeutic uselaw.inventionGonadotropin-Releasing HormoneGynécologieRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointBiological Markers -- bloodNorethindrone -- therapeutic useProspective StudiesTreatment FailureProspective cohort studyTriptorelin PamoateEstradiolLymphoma Non-HodgkinLymphoma -- drug therapyMiddle AgedTriptorelinHodgkin DiseasePremature ovarian failureLuteolytic AgentsOncologyHodgkin Disease -- drug therapyDrug Therapy CombinationFemaleEstradiol -- bloodmedicine.drugAdultAntineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effectsmedicine.medical_specialtyNorethisteronemedicine.drug_classUrologyFollicle Stimulating Hormone -- bloodGonadotropin-releasing hormone agonistmedicineHumansGynecologyChemotherapybusiness.industrymedicine.diseaseLuteolytic Agents -- therapeutic useCancérologieLymphoma Non-Hodgkin -- drug therapyPremenopausePrimary Ovarian Insufficiency -- blood -- chemically induced -- prevention & controlFollicle Stimulating HormoneNorethindronebusinessBiomarkersFollow-Up Studies
researchProduct

Profile of intranasal corticosteroids in italy: Safety, cost/effectiveness, local and systemic adverse effects

2014

Background: Allergic Rhinitis is a common and often debilitating disease that affect, nowadays, not only young people. For this reason an effective treatment is necessary to minimize the impact of allergic rhinitis in general population. Objective: The aim of this review is to inquire intranasal corticosteroids. Results: We have obtained several randomized, double-blind, placebo-controlled clinical trials, by a MEDLINE search. We analyzed the safety profile, the adverse effects described by the authors, the relation between cost/effectiveness. We have made a search for trade profile, dosage and chemical characteristics by on-line handbook. Discussion: Several studies demonstrate that intran…

Corticosteroids Fluticasone Adverse effects
researchProduct

Italian multicentric survey on laparoscopic spleen surgery in the pediatric population.

2007

Abstract Background: Some technical aspects of laparoscopic spleen surgery still are debated, although efforts have been made to standardize them. The position of the patient, the approach to the spleen, vessel identification and division, and spleen extraction can vary from center to center. Methods: This retrospective muticentric study led by the Societa` Italiana di Videochirurgia Infantile (SIVI) examined indications, surgical details, and complications of laparoscopic spleen surgery in the pediatric population during a 5-year period. Results: The study period from January 1999 to December 2003 (5 years) involved nine centers and included 85 patients with a mean age of 10 years (range, …

Laparoscopic surgeryMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentSplenectomySpleenAdolescent Age Distribution Child Child; Preschool Data Collection Female Hematologic Diseases; complications/diagnosis Humans Incidence Intraoperative Complications; diagnosis/epidemiology Italy Laparoscopy; adverse effects/methods Male Pediatrics; methods Postoperative Complications; diagnosis/epidemiology Prognosis Retrospective Studies Risk Assessment Severity of Illness Index Sex Distribution Splenectomy; adverse effects/methods Splenic Diseases; diagnosis/etiology/surgery Survival AnalysisPediatricsRisk AssessmentSeverity of Illness IndexmethodsAge DistributionPostoperative ComplicationsmedicineHumansSex DistributionLaparoscopyChildPreschoolIntraoperative ComplicationsRetrospective StudiesSplenic Diseasesadverse effects/methodsmedicine.diagnostic_testdiagnosis/epidemiologybusiness.industryData CollectionIncidenceComplications — Fenestration — Laparoscopic splenectomy — Multicentric survey — Spleen —technical detailscomplications/diagnosismedicine.diseasePrognosisdiagnosis/etiology/surgeryHematologic DiseasesSurvival AnalysisEndoscopySurgerymedicine.anatomical_structureItalyChild PreschoolSplenectomySurgeryFemaleLaparoscopySplenic diseasebusinessComplicationAbdominal surgery
researchProduct

Effect of part-time cardiac catheterization facilities in patients with acute myocardial infarction

2017

Although the easy availability of invasive cardiac care facilities is associated with an increase in their use, their influence on outcomes is not clear. We sought to investigate whether a newly available cardiac catheterization laboratory (CCL) performing percutaneous coronary intervention (PCI) on a part-time (PT) basis might improve outcomes in patients with acute myocardial infarction (AMI).This was an observational cohort study that included all consecutive patients with AMI admitted to a secondary-level hospital in Spain before and after the PT-CCL opened in January 2006: during 1998-2005 and 2006-2014, respectively. All-cause in-hospital and long-term mortality were the co-primary en…

MaleCardiac Catheterizationmedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentMyocardial InfarctionLong Term Adverse Effects030204 cardiovascular system & hematologyLower riskAngina PectorisAngina03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineHospital AdministrationInternal medicineSecondary PreventionmedicineHumansHospital Mortalitycardiovascular diseases030212 general & internal medicineMyocardial infarctionCardiac catheterizationbusiness.industryPercutaneous coronary interventionLength of Staymedicine.diseaseSurvival AnalysisOrganizational InnovationSpainCardiac Care FacilitiesEmergency medicineConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

The importance of being “responder” in cardiac resynchronization therapy

2016

MaleCardiac resynchronization therapy (CRT)medicine.medical_specialtyPrognosimedicine.medical_treatmentCardiac resynchronization therapyLong Term Adverse EffectsLong Term Adverse Effect030204 cardiovascular system & hematologySeverity of Illness IndexVentricular Function LeftCardiac Resynchronization Therapy03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumans030212 general & internal medicineAgedMonitoring PhysiologicRetrospective StudiesHeart FailureVentricular Remodelingbusiness.industryResponderMiddle AgedSurvival AnalysisNon respondersHeart failure (HF)Treatment OutcomeNon-responderItalyCardiologyFemaleSurvival AnalysiCardiology and Cardiovascular MedicinebusinessHumanInternational Journal of Cardiology
researchProduct

Antibiotic Coating of the Artificial Urinary Sphincter (AMS 800): Is it Worthwhile?

2016

Objective To investigate the impact of the antibiotic coating InhibiZone on the infection and explantation rates of the AMS 800 in comparison to the AMS 800 without InhibiZone. Materials and Methods We retrospectively identified 305 patients with an AMS 800 in a multicenter cohort study. Patients were subsequently divided into InhibiZone and without InhibiZone-coated groups. Infection and explantation rates were analyzed by univariate and consecutively by multivariate logistic regression adjusted to variable risk factors. The infection-free interval was estimated by Kaplan-Meier plot and compared by the log-rank test. A P value below .05 was considered statistically significant. Results We …

Malemedicine.medical_specialtyProsthesis-Related InfectionsMultivariate analysismedicine.drug_classUrologyAntibiotics030232 urology & nephrologyLong Term Adverse EffectsProsthesis DesignLogistic regressionRisk AssessmentGastroenterologyCohort StudiesArtificial urinary sphincter03 medical and health sciences0302 clinical medicineCoated Materials BiocompatibleRisk FactorsInternal medicineOutcome Assessment Health CaremedicineHumansAgedUnivariate analysisbusiness.industrySignificant differenceMiddle AgedAnti-Bacterial AgentsSurgeryUrinary Incontinence030220 oncology & carcinogenesisUrinary Tract InfectionsCohortUrinary Sphincter ArtificialFemalebusinessCohort studyUrology
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort

2020

PURPOSE The HIT-2000-BIS4 trial aimed to avoid highly detrimental craniospinal irradiation (CSI) in children < 4 years of age with nonmetastatic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local radiotherapy. PATIENTS AND METHODS From 2001-2011, 87 patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for nonresponse or progression. After 2006, local radiotherapy was introduced for nonresponders or patients with classic medulloblastoma (CMB) or large-cell/anaplastic medulloblastoma (LCA). DNA methylation profiles of infantile sonic hedgehog-activated medulloblastoma (SHH-INF) were subdivided i…

OncologyMaleCancer ResearchMedizinradiotherapy [Medulloblastoma]Neuropsychological Testsadverse effects [Cranial Irradiation]Craniospinal Irradiation0302 clinical medicinemortality [Cerebellar Neoplasms]drug therapy [Medulloblastoma]Early childhoodProspective Studiesddc:618Systemic chemotherapyCerebellar Neoplasms / mortality3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolMedulloblastoma / radiotherapyFemalemortality [Medulloblastoma]medicine.medical_specialtyCerebellar Neoplasms / drug therapyCerebellar Neoplasms / radiotherapyMEDLINEMedulloblastoma / drug therapyadministration & dosage [Methotrexate]03 medical and health sciencesInternal medicinedrug therapy [Cerebellar Neoplasms]medicineHumansddc:610Cerebellar NeoplasmsMedulloblastomaCranial Irradiation / adverse effectsbusiness.industryEditorialsInfantMethotrexate / administration & dosageDNA Methylationmedicine.diseaseClinical trialMethotrexateMedulloblastoma / mortalityradiotherapy [Cerebellar Neoplasms]Cranial IrradiationbusinessValidation cohort030217 neurology & neurosurgeryMedulloblastoma
researchProduct